KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gains from Investment Securities: 2016-2024

Historic Gains from Investment Securities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $15.2 million.

  • Amneal Pharmaceuticals' Gains from Investment Securities rose 111.19% to $129,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 2927.02%. This contributed to the annual value of $15.2 million for FY2024, which is 204.99% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Gains from Investment Securities is $15.2 million, which was up 204.99% from -$14.5 million recorded in FY2023.
  • Amneal Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $100.1 million during FY2020, with a 5-year trough of -$15.6 million in FY2021.
  • Its 3-year average for Gains from Investment Securities is $4.5 million, with a median of $12.6 million in 2022.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Gains from Investment Securities spiked by 1,521.16% in 2020, and later plummeted by 214.61% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Gains from Investment Securities stood at $100.1 million in 2020, then crashed by 115.54% to -$15.6 million in 2021, then spiked by 181.30% to $12.6 million in 2022, then tumbled by 214.61% to -$14.5 million in 2023, then skyrocketed by 204.99% to $15.2 million in 2024.